Press Releases

 
Press Releases
Date Title and Summary View
Oct 27, 2014 PORTLAND, Ore., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its third quarter financial results on Monday, Novembe...
Oct 14, 2014 -  Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2 -  Extends patent coverage to three main markets, U.S., EU and now Japan PORTLAND, Ore., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceut...
Oct 8, 2014 PORTLAND, Ore., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced the Notice of Allowance of a U.S. patent application covering methods of ...
Sep 25, 2014 PORTLAND, Ore., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) today announced the release of a report prepared by the former Special Committee of Galena's Board of Directors regarding the Company's 2012-2014 market visibility campaigns and the sale of shares by insiders in the first quarter of 2014. The Executive Summary o...
Sep 9, 2014 PORTLAND, Ore., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced the first patient has been dosed in the GALE-401, or Anagrelide Controll...
Sep 3, 2014 PORTLAND, Ore., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will...
Aug 21, 2014 PORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief ...
Aug 11, 2014 Abstral® (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014. U.S. license of Zuplenz® (ondansetron) oral soluble film expands portfolio to two commercial products. On track to reach two significant milestones in 2H 2014: completing enrollment activities in the NeuVax™ (nelipepi...
Jul 29, 2014 PORTLAND, Ore., July 29, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its second quarter financial results on Monday, August...
Jul 22, 2014 Novel, rapidly dissolving oral PharmFilm® enables faster absorption, increased convenience and better compliance for patients. Planned launch in multiple indications—chemotherapy-, radiation- and post operative-induced nausea and vomiting—in early 2015. FDA-Approved product to be added to Galena's established oncology com...
Page:
1
... NextLast
= add release to Briefcase